Shots: The P-II CheckMate -650 trial involves assessing of Opdivo (nivolumab, 1mg/kg) + Yervoy (ipilimumab, 3mg/kg) in patients with mCRPC P-II study result in asymptomatic or minimally symptomatic patients & […]readmore
Tags : BMS
Shots: The approval is based on P-III CheckMate-214 study results assessing Opdivo (3mg/kg) + low-dose Yervoy(1mg/kg) vs sunitinib (50mg, qd) in patients with previously untreated advance RCC P-III Checkmate-214 study […]readmore
Shots: BMS acquires Celgene, in all stock transaction for $74B. Celgene to receive $50/share, 1 BMS share and 1 Contingent Value Right (CVR) of $9 cash as regulatory milestone for […]readmore
Shots: Taisho to acquire BMS’ UPSA Consumer Health Business for $1.6B, in all stock transaction with the put option. The transaction is expected to close in H1’19 The focus of the agreement […]readmore